The aim is to analyze how the advances in pulmonary thromboembolism (PTE) may
influence its therapeutic protocol, focusing on the anti-vitamin K (AVK) start. Narrative review …

Pulmonary embolism (PE) is a frequent, serious and multifactorial disease, the incidence of
which increases with advanced age. In the absence of pathognomonic clinical signs or …

Optimal long-term anticoagulation post-PE should be guided by straightforward and
individual risk assessment strategies. The array of indications for DOACs has gotten wider in …

Background After stopping a 3 to 6 months course of oral anticoagulation for a first episode
of idiopathic venous thromboembolism (VTE), the risk of recurrent VTE is high (10% per …

None of the current clinical practice guidelines offers clear recommendations on the optimal
duration of anticoagulation after pulmonary embolism. Previous studies have reported that …

Background Extended oral anticoagulant (OA) use is recommended in patients with acute
pulmonary embolism (PE) who require secondary thromboprophylaxis. Nevertheless, the …

Importance The optimal duration of anticoagulation after a first episode of unprovoked
pulmonary embolism is uncertain. Objectives To determine the benefits and harms of an …

The treatment of choice in pulmonary embolism (PE) is anticoagulation both in the acute
phase and long-term, provided that there are no contraindications. A differentiation must be …

Pulmonary embolus (PE) carries a significant impending morbidity and mortality, especially
in intermediate and high-risk patients, and the choice of initial anticoagulation that allows for …

Background The pathophysiology of chronic thromboembolic pulmonary hypertension
(CTEPH) is not fully understood. Poor-quality anticoagulation may contribute to a higher risk …